Last updated: February 15, 2026
Overview
ND: 00093-7679 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for spinal muscular atrophy (SMA). Launched in 2019, Zolgensma is marketed as a one-time treatment offering a potential cure for SMA, a rare genetic disorder affecting infants and children.
Market Size and Demand
- Prevalence of SMA: Approximately 1 in 10,000 live births globally. The US reports about 400-500 new SMA cases annually among infants.
- Patient Population:
- Infants with Type 1 SMA: Major target group; accounts for roughly 60% of SMA cases.
- Older children and adults: Smaller subsets, with fewer approved treatment options.
- Market Penetration:
- As of 2022, estimates indicate over 2,000 patients globally have been treated with Zolgensma.
- The US accounts for about 75-80% of sales, given early access and reimbursement policies.
Competitive Landscape
- Existing therapies:
- Spinraza (nusinersen) by Biogen, approved in 2016, administered via intrathecal injection.
- Evrysdi (risdiplam) by Roche, approved in 2020, orally administered.
- Differentiators:
- Zolgensma's one-time IV infusion contrasts with ongoing treatment cycles of competitors.
- Higher upfront cost but potentially lower lifetime treatment costs.
Pricing and Reimbursement
- List Price: $2.1 million per dose in the US, making it one of the most expensive therapies.
- Pricing Strategy:
- Based on the therapy's curative potential and innovation.
- Used as a benchmark for gene therapy valuation.
- Reimbursement negotiated through payers, with outcomes-based agreements in some cases.
- Cost-Effectiveness:
- Cost per quality-adjusted life year (QALY) is under ongoing debate.
- Payers weigh the high upfront costs against long-term savings from reduced care needs.
Market Outlook and Growth Projections
| Year |
Estimated Global Prescriptions |
Expected Revenue (USD Billions) |
Notes |
| 2022 |
2,300 |
4.8 |
Steady initial growth in US and Europe. |
| 2023 |
3,400 |
7.1 |
Expansion to more countries. |
| 2024 |
4,500 |
9.5 |
Increased diagnosis and awareness. |
| 2025 |
5,800 |
12.0 |
Potential new indications and expanded coverage. |
- Market Penetration Growth: Driven by expanded indications, improved diagnostics, and increased awareness.
- Potential Market Expansion: Pending approval for broader age groups and later onset SMA forms.
Pricing Projections (2023-2025)
- Price Stability: Expected to remain near current levels in the US, with possible discounts or outcome-based pricing.
- Regional Variance:
- Europe and Asia-Pacific could see prices between 20-50% lower due to cost negotiations.
- Emerging markets likely to have limited access initially, impacting regional sales.
Regulatory and Policy Impact
- FDA and EMA: Approve expanded indications, facilitating sales growth.
- Orphan Drug Policies: Maintain incentives but also limit price increases.
- Value-Based Agreements: Increasingly adopted, tying reimbursement to clinical outcomes, which could moderate revenue growth but improve market access.
Conclusion
Zolgensma's market is characterized by high unmet need, limited competition, and a premium pricing model. Long-term growth depends on expanded labels, increased diagnosis rates, payer acceptance, and potential cost adjustments in non-US regions.
Key Takeaways
- Zolgensma's global uptake is accelerating, with prescriptions projected to reach nearly 6,000 annually by 2025.
- The therapy maintains a premium price point, with US list prices at approximately $2.1 million per dose.
- Expansion into broader SMA populations and new markets will drive revenue growth.
- Reimbursement strategies, especially outcomes-based agreements, influence pricing stability.
- Competition from Spinraza and Evrysdi remains strong, but Zolgensma’s single-dose modality offers a distinct advantage.
FAQs
-
What factors influence the high cost of Zolgensma?
Its development as a curative gene therapy, manufacturing complexity, and the rarity of SMA justify premium pricing.
-
How does Zolgensma compare economically to Spinraza and Evrysdi?
Despite higher upfront costs, it may reduce lifetime treatment expenses and care costs, but payers' cost-effectiveness assessments vary.
-
Are there ongoing efforts to expand Zolgensma’s indications?
Yes. Clinical trials are exploring use in later-onset SMA and broader age groups, which could expand the treated population.
-
What are the risks affecting Zolgensma’s market growth?
Regulatory delays, manufacturing challenges, or new competitors could impact sales. Reimbursement policies also influence access.
-
What is the potential for new gene therapies to disrupt this market?
Emerging gene therapies targeting SMA or complementary indications could provide alternatives, but Zolgensma’s established presence and pricing give it a competitive edge in the near term.
References
[1] Novartis. “Zolgensma (onasemnogene abeparvovec-xioi) Important Safety Information,” 2022.
[2] MarketResearch.com. “Global Market Analysis for SMA Treatments,” 2022.
[3] FDA Approvals. “Zolgensma Approved for SMA,” 2019.
[4] IQVIA. “Global Prescription Data,” 2022.
[5] EvaluatePharma. “Gene Therapy Market Outlook,” 2022.
